Hepatitis B Core Antibody Test

Most people who have been exposed to hepatitis B never know it. The virus can enter your body, trigger an immune response, and either resolve quietly or settle into a chronic infection that causes no symptoms for decades. A positive hepatitis B core antibody (anti-HBc) result is the one marker that catches every scenario: acute infection, chronic infection, and resolved infection that happened years ago. It is the most sensitive single indicator of whether hepatitis B virus has ever been in your body.

This matters because hepatitis B is not just a short-term illness. Even after the virus appears to clear, it can hide in liver cells and reactivate under certain conditions, particularly if your immune system is suppressed by medication. Knowing your anti-HBc status gives you a piece of information that no other single test provides: a definitive answer about whether you have ever been infected.

What This Test Tells You

Anti-HBc (hepatitis B core antibody) is produced by your immune system's B cells in response to a protein found inside the hepatitis B virus particle, called the core antigen. This protein is only present during actual infection. It is not included in the hepatitis B vaccine. That distinction is the key to anti-HBc's value: if this antibody is in your blood, you were infected at some point. Vaccination alone will never produce it.

The test comes in two forms. The IgM version detects antibodies that appear during acute or very recent infection, typically lasting about six months. The total anti-HBc test (which is what most labs run) detects both the early IgM antibodies and the long-lasting IgG antibodies that persist for life. There is no commercially available test that measures IgG anti-HBc alone, so "total anti-HBc" is the standard.

Reading Your Result in Context

Anti-HBc is a qualitative test. Your result is either positive (reactive) or negative (non-reactive). There are no numerical ranges, no "optimal" levels, and no gray zones. But a positive result means very different things depending on what other hepatitis B markers show alongside it. You cannot interpret anti-HBc alone.

The pattern that causes the most confusion is "isolated anti-HBc," where anti-HBc is positive but both the surface antigen and the surface antibody are negative. This occurs in roughly 0.8% of the general U.S. population and in 7% to 19% of people living with HIV. The most common explanation is a past infection where the surface antibody faded over time. Less commonly, it can signal occult hepatitis B, where the virus is hiding in liver tissue at levels too low for surface antigen tests to detect. In rare cases, particularly in populations with low hepatitis B prevalence, it may be a false positive.

Liver Disease and Cancer Risk

Chronic hepatitis B infection, marked by a persistently positive surface antigen alongside anti-HBc, is one of the strongest known risk factors for liver cancer and cirrhosis. But even a positive anti-HBc without active surface antigen carries meaningful risk signals.

A Korean cohort study following over 609,000 adults for a median of 9 years found that people with isolated anti-HBc positivity (no active surface antigen) had about 69% higher risk of dying from liver disease compared to people with no hepatitis B exposure. Among those who also had elevated liver scarring scores (measured by a calculation called FIB-4), the risk of liver cancer death was dramatically amplified.

In people with fatty liver disease (NAFLD), a positive anti-HBc is associated with roughly twice the odds of progressing to cirrhosis. One study of 489 biopsy-confirmed fatty liver disease cases found cirrhosis rates of 18.8% in the anti-HBc positive group versus 7.5% in the negative group. A separate analysis of over 3,200 fatty liver disease cases from the NHANES III survey, followed for a median of 22 years, found that anti-HBc positivity was linked to 54% higher cancer-related mortality and 69% higher odds of advanced liver scarring.

A meta-analysis pooling data from over 44,500 people across 26 studies found that anti-HBc positivity in people without active surface antigen but with existing chronic liver disease carried a 67% higher risk of liver cancer.

Cancers Beyond the Liver

Hepatitis B's reach extends beyond the liver. A large Chinese case-control study of over 50,000 cancer cases found that a specific pattern of past hepatitis B exposure (positive anti-HBc with negative surface antigen and negative surface antibody) was associated with increased risk of esophageal cancer (about 46% higher) and stomach cancer (about 20% higher). Data from the China Kadoorie Biobank, a prospective cohort of nearly half a million people, also linked active hepatitis B infection to elevated risks of stomach cancer, pancreatic cancer, and lymphoma.

Heart Disease: A Complicated Picture

The relationship between hepatitis B and cardiovascular disease is not straightforward. A meta-analysis of over 65,000 hepatitis B-infected people and 534,000 controls found no overall association between hepatitis B infection and coronary heart disease risk. An analysis of NHANES data actually found that anti-HBc positivity was associated with lower incidence of ischemic heart disease.

However, the China Kadoorie Biobank study of 477,000 adults found that active hepatitis B infection (surface antigen positive) was linked to a 25% higher risk of bleeding strokes in the brain, even though it was associated with slightly lower risk of other heart conditions. In short, hepatitis B does not appear to be a major driver of typical heart attacks, but its relationship with certain types of stroke warrants attention.

Overall Mortality

A prospective study of nearly 476,000 Chinese adults followed for about 10 years found that people with chronic hepatitis B (surface antigen positive) had roughly double the overall mortality risk. The excess deaths were driven primarily by liver cancer (about 14 times higher risk), infections (about 10 times higher), and digestive diseases (about 7 times higher). Even past exposure without active infection carried a signal: a U.S. NHANES analysis found that past hepatitis B exposure (anti-HBc positive, surface antigen negative) was linked to 29% higher overall mortality, and among people with alcoholic liver disease, the risk was more than doubled.

The Reactivation Risk You Need to Know About

This is the single most actionable reason to know your anti-HBc status. If you are anti-HBc positive, even without active infection, certain medications can reawaken the virus. Immunosuppressive drugs used for cancer treatment, autoimmune conditions, and organ transplants can lower your immune defenses enough for hidden hepatitis B to flare. Reactivation can cause severe liver inflammation, liver failure, and in some cases death.

Reactivation occurs in 8% to 18% of surface antigen-negative, anti-HBc positive people receiving anticancer therapies, and about 1.7% of those receiving anti-rheumatic medications. Drugs like rituximab and ofatumumab carry especially high reactivation risk. Current guidelines recommend that anyone starting immunosuppressive therapy should be tested for both surface antigen and anti-HBc beforehand, so that preventive antiviral medication can be started if needed.

Why Standard Screening Used to Miss This

Until recently, many standard hepatitis B screening panels included only the surface antigen (HBsAg) and the surface antibody (anti-HBs), leaving anti-HBc out entirely. That two-marker approach could tell you if you had active infection or if you were immune, but it missed people with past exposure who had lost their surface antibody over time. It also missed the reactivation risk group.

The CDC now recommends triple-panel testing (surface antigen, surface antibody, and anti-HBc) for all adults aged 18 and older at least once in their lifetime. This shift happened because roughly two-thirds of chronically infected people do not know they carry the virus, and antiviral treatment can significantly reduce the risk of liver disease progression, cirrhosis, and cancer.

When Results Can Be Misleading

Modern anti-HBc assays have a specificity of 99.88% in blood donors and 96.85% in people with non-hepatitis B medical conditions. That means false positives are uncommon but not impossible, especially in populations where hepatitis B prevalence is low. If you test positive for anti-HBc but have no risk factors and both the surface antigen and surface antibody are negative, a false positive is one possibility. Repeat testing can help clarify.

• Intravenous immunoglobulin (IVIG): if you have received IVIG in the past four months, your anti-HBc result may reflect antibodies from the pooled donor product rather than your own immune response. One pediatric study found that 50% of positive anti-HBc results in their cohort were attributable to recent IVIG infusion.
• Corticosteroid therapy: prolonged courses of corticosteroids like prednisolone can suppress your immune system's antibody production, potentially causing a genuinely positive anti-HBc result to temporarily become undetectable. Antibody levels rebound after the medication is stopped.
• Biotin supplements: high-dose biotin (sometimes sold as a hair and nail supplement) can interfere with certain lab assay methods that use a biotin-based chemistry, producing false positive or false negative results. One study found 100% false positivity in anti-HBc negative samples spiked with biotin.

Standard pre-test variables like fasting, time of day, exercise, and recent illness have not been documented to affect anti-HBc results. Unlike metabolic markers that fluctuate with meals or stress, anti-HBc is a stable antibody that, once established, persists at detectable levels for life.

Tracking Over Time

For most biomarkers, serial trending reveals more than a single snapshot. Anti-HBc is different. Because it is a qualitative test (positive or negative) and because it persists for life once established, you do not need to retest periodically just to confirm that a confirmed positive result is still positive. It will be.

The value of repeat testing comes in specific scenarios. If your initial result is an isolated positive (no surface antigen, no surface antibody) and there is concern about a false positive, retesting confirms or refutes the original finding. If you are anti-HBc positive and starting immunosuppressive therapy, your medical team will monitor hepatitis B virus DNA levels over time to watch for reactivation, rather than re-checking anti-HBc itself. And if you tested negative in the past but have new risk factors for hepatitis B exposure, retesting makes sense to check for new infection.

For the general population, the CDC's recommendation of at least one triple-panel screening (including anti-HBc) in adulthood is the baseline. If that screening is negative and you have no new exposure risks, you do not need to repeat it. If it is positive, the follow-up path depends on the full serologic pattern, not on serial anti-HBc monitoring.